Browsing: ResMed

NEW YORK and SAN DIEGO – A new partnership will bridge technology from Eight Sleep with sleep insights from Resmed, helping people in the United States and Australia better understand their sleep health, the companies say.

Eight Sleep, a leading AI-powered sleep technology company, and Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced they are partnering to help people in the U.S. and Australia better understand their sleep health by bridging Eight Sleep’s technology with sleep insights…

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge

ResMed (ASX:RMD) sits at the intersection of medical devices, sleep health and digital healthcare. At the time of writing on 9 September 2026, the shares were priced at A$30.74. For investors, the more durable question is how operating growth, product adoption and portfolio execution translate into Earnings momentum over time

SAN DIEGO – Resmed has a new collaboration with 23XI Racing and its NASCAR Cup Series driver Tyler Reddick to encourage more people to recognize the signs of sleep apnea and seek diagnosis and treatment. After being diagnosed with obstructive sleep apnea (OSA) and starting continuous positive airway pressure (CPAP) therapy in early 2026, Reddick went…

ResMed Inc. (NYSE:RMD) is one of the most undervalued large cap stocks to buy according to analysts. On June 1, ResMed finalized its acquisition of Noctrix Health, a medical device company known for developing non-pharmacologic wearable therapeutics. This strategic move expands ResMed’s clinical sleep health portfolio into the treatment of Restless Legs Syndrome/RLS, which is…

ResMed Inc (ASX:RMD) closed at AUD 31.48 at the close of trading on 6 August 2026, up 0.29% for the session. The broader S&P/ASX 200 Health Care (ASX: XHJ) Index advanced +0.81% to close at 28,235.50 points, while the S&P/ASX 200 (ASX: XJO) gained +0.47% to finish the day at 9,271.60 points

ResMed Inc (ASX:RMD) is a global medical device and digital health company that develops products for the diagnosis and treatment of sleep disorders and respiratory conditions. The company’s primary products include CPAP and other positive airway pressure devices used in the treatment of obstructive sleep apnea

ResMed (RMD) has drawn investor attention after recent share price gains over the past week and month, set against weaker returns over the past year and year to date

Resmed has agreed to sell its MatrixCare business in a $490m cash deal to PE firm Frazier Healthcare Partners, allowing it to dedicate its focus to its sleep health-related business interests